Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Until today this year the stock’s price performance recorded an increase of 25.13%. However, over the last six months, the performance has been weaker by 46.57%. The price of MYGN increased 14.70% over the last 30 days. And in the last five days, it has surged by 23.01%.
Myriad Genetics, Inc.’s stock has seen a smooth market performance. The company’s stock achieved a 1-year high of $24.21 on 06/30/23, and the lowest price during that time was $13.82, recorded on 10/30/23.
52-week price history of MYGN Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Myriad Genetics, Inc.’s current trading price is -1.07% away from its 52-week high, while its distance from the 52-week low is 73.30%. The stock’s price range for this period has been between $13.82 and $24.21. The Healthcare sector company’s shares saw a trading volume of about 2.59 million for the day, which was higher than the average daily volume of 0.66 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Myriad Genetics, Inc. (MYGN) has experienced a quarterly rise of 8.96% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.15B and boasts a workforce of 2700 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 20.86, with a change in price of +3.07. Similarly, Myriad Genetics, Inc. recorded 684,221 in trading volume during the last 100 days, posting a change of +14.70%.
MYGN’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for MYGN stands at 0.19. Similarly, the long-term debt-to-equity ratio is also 0.17.
MYGN Stock Stochastic Average
As of today, the raw stochastic average of Myriad Genetics, Inc. over the past 50 days is 96.03%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 96.03%. Additionally, the Stochastic %K and %D values for the company were 75.38% and 62.54%, respectively, over the past 20 days.
